Dr. Yi Fang 方仪
Chief Physician
Department of Breast Surgery, Cancer Hospital, Chinese Academy of Medical Sciences (National Cancer Center), Beijing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Comprehensive breast cancer treatment, minimally invasive tumor removal, breast-conserving and function-preserving surgery, post-tumor resection plastic surgery, oncoplasty, and immediate reconstruction using autologous tissue, expanders, or implants.
Dr. Fang earned a medical doctorate from Peking Union Medical College in 2003. As a professorial chief physician and doctoral supervisor, Dr. Fang leads the breast cancer group for the National Public Health Major Project on early cancer diagnosis and treatment. Research focuses on immediate breast reconstruction after mastectomy. Dr. Fang has led or participated in over 20 research projects and published more than 30 articles in the past five years.
Professional roles
- Vice Chair and Secretary-General, Breast Disease Branch, China International Exchange and Promotion Association for Medical and Healthcare
- Vice Chair, Integrated Rehabilitation Committee for Breast Tumors, China Anti-Cancer Association
- Member, Breast Cancer Professional Committee, China Anti-Cancer Association
- Member, Breast Oncology Group, Oncology Branch, Chinese Medical Association
Name order: in Chinese the family name comes first (Fang Yi). Papers usually list the name as Yi Fang or Fang Y.
Selected publications
110 papers on PubMed matched by name and affiliation; 18 as first or senior author since 2016. Most recent first- or senior-author papers:
- Front Immunol, 2026 (senior author): Survival outcomes of axillary de-escalation following neoadjuvant chemo-immunotherapy in clinically node-positive triple-negative breast cancer: a national cancer database study. PubMed 42488634
- BMJ Open, 2026 (senior author): PERSEVERE: longitudinal assessment of quality of life and treatment toxicities in Chinese breast cancer patients - a multicentre cohort study protocol. PubMed 41922058
- QJM, 2026 (senior author): Mapping the Heterogeneity of Mortality: Age- and Race-Specific Trajectories in 839,698 Breast Cancer Survivors. PubMed 41719198
- Cancer Innov, 2025 (senior author): Global, Regional, and National Burden of Breast Cancer in Adolescents and Young Adults Aged 15-39 Years From 1990 to 2021 Based on the Global Burden of Disease Study 2021. PubMed 40487561
- Breast Cancer Res, 2025 (senior author): Dissecting the tumor microenvironment in primary breast angiosarcoma: insights from single-cell RNA sequencing. PubMed 40474296
- Discov Oncol, 2025 (senior author): Nomogram construction for overall survival in breast angiosarcoma based on clinicopathological features: a population-based cohort study. PubMed 40100579
- J Control Release, 2025 (senior author): DNA tetrahedral nanoparticles: Co-delivery of siOTUD6B/DOX against triple-negative breast cancer. PubMed 39549731
- Front Immunol, 2024 (senior author): Single-cell sequencing unveils mitophagy-related prognostic model for triple-negative breast cancer. PubMed 39559367
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion